Docebo (DCBO) Research & Development (2019 - 2026)

Docebo (DCBO) has reported Research & Development for 8 consecutive years, with $13.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 2.29% year-over-year to $13.0 million; the trailing twelve-month figure through Jun 2026 stood at $52.5 million (up 7.44% YoY), and the FY2025 full-year result was $50.1 million, up 14.15% from the prior year.
• Research & Development retreated to $13.0 million in Q2 2026 per DCBO's latest filing, from $15.5 million in the prior quarter.
• Across five years, Research & Development topped out at $15.5 million in Q1 2026 and bottomed at $6.1 million in Q3 2022.
• Historically, Research & Development has averaged $10.2 million across 5 years, with a median of $10.6 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Research & Development jumped 68.24% in 2023, then grew 2.29% in 2026.
• Over 5 years, Research & Development stood at $6.4 million in 2022, then surged by 41.49% to $9.0 million in 2023, then grew by 28.31% to $11.6 million in 2024, then rose by 4.63% to $12.1 million in 2025, then advanced by 7.24% to $13.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $13.0 million, $15.5 million, and $12.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.